# A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma

> **NCT07063758** · — · ACTIVE_NOT_RECRUITING · sponsor: **National Taiwan University Clinical Trial Center** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma

## Interventions

- **OTHER:** Biomarker Analysis

## Key facts

- **NCT ID:** NCT07063758
- **Lead sponsor:** National Taiwan University Clinical Trial Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07063758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07063758, "A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07063758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*